Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Ординатура / Хирургия / @xirurgi_2025 / @xirurgi_2025 - 380 - файл

.pdf
Скачиваний:
0
Добавлен:
29.08.2026
Размер:
47 Мб
Скачать
10 Dressing inBurns
https://t.me/medicina_free
109
• Acetic acid (AA): It is another antiseptic solu­tion that has been applied as a topical antimi­crobial agent to wounds, including burns.
• A few heterogeneous studies involving a lim­ited number of grossly contaminated or infected wounds suggest that 1–5% AA solu­tions have been effective; however, pain, itch­ing, and burning of the skin have been reported when this concentration range has been applied. There are no clinical studies of AA use in burn patients. One invitro study found that 3% AA was bactericidal against a broad range of burn wound pathogens [35].
• Povidone-iodine and chlorhexidine solutions have been used as topical antiseptic agents on burn wounds. Both agents are effective against a wide range of bacteria and fungi.
• Presently, both agents are commonly used as soap solutions to clean wounds, especially as a “prep” of the skin, and burn wounds prior to surgery.
• Chlorhexidine diphosphanilate cream: It has been tested in burn patients, and the agent is though difcult to apply and painful at con­centrations above 0.5% [36].
10.6 Chemical Burns
Chemical burn injuries represent only 3% of all burns; many compounds have the potential to induce chemical burns due to exposure to indus­trial or household cleaning substances or pesti­cides. Most commonly affected body areas are face, eyes, and extremities. All burn wounds, whether due to chemical or thermal sources, have in common protein denaturation, as changes in pH or dissolution of surrounding lipids may sta­bilize a protein and disrupt its function.
Severity of a chemical burn injury is deter-
mined by several factors:
• Concentration of chemical agent.
• Quantity of chemical agent.
• Manner and duration of skin contact.
• Extent of penetration.
• Mechanism of action.
• Phase of agent (liquid, solid, and gas).
Within these groups, there are different cate­gories of compounds. Chemical burns are often described as acidic or alkaline [37, 38]. Acids act as proton donors in the biological system, and strong acids have a pH<2. Alkali, or basic mate­rial, capable of producing injury, typically has a pH > 11.5 [39]. In general, alkaline materials cause more injury than acidic compounds. Acids cause coagulation necrosis with protein precipi­tation, whereas the reaction to alkali is “liquefac­tion” necrosis, allowing the substance to penetrate deeper into the injured tissue [40].
Most important aspects of rst aid for chemi­cal burns involve agent removal from contact with the patient. This requires the removal of all potentially contaminated clothing and copious irrigation.
Irrigation of chemical burns requires the pro­tection of healthcare providers, in order to pre­vent additional injuries. Immediate copious irrigation has been shown to reduce the extent and depth of injury, especially to eyes [41]. Thirty minutes to 2h of lavage may be necessary.
The use of neutralizing agents is discouraged. The practical problems encountered with their use are exothermic reactions causing further ther­mal damage. Regional poison control centers for household chemicals or unidentied agents can be valuable resources for potential systemic tox­icity and side effects of a particular agent.
References
1. Institute of Medicine. Clinical practice guidelines we can trust. Washington, DC: The National Academies Press; 2011. p.16.
2. Leon-Villapalos J, Barret JP. Surgical Repair of the Acute Burn Wound: Who, When, What Techniques? What Is the Future?. J Burn Care Res. 2023:44.
3. ISBI “Practice Guidelines for Burn Care” ISBI Practice Guidelines Committee; Steering Subcommittee; Advisory Subcommittee.
4. Sarkar A, Rakshit P, Majumdar BK, et al. Use of cadaveric skin allograft in management of deep burn wounds: our experience. Int J Basic Appl Med Sci. 2013;3:186–8.
5. Obeng MK, McCauley RL, Barnett JR. Cadaveric allograft discards as a result of positive skin cultures. Burns. 2001;27:267–71.
6. Kua EH, Goh CQ, Ting Y, Chua A, Song C.Comparing the use of glycerol preserved and cryopreserved allo-
110
https://t.me/medicina_free
A. Mangia et al.
genic skin for the treatment of severe burns: differ­ences in clinical outcomes and invitro tissue viability. Cell Tissue Bank. 2012;13:269–79.
7. Böttcher-Haberzeth S, Biedermann T, Reichmann E.Tissue engineering of skin. Burns. 2010;36:450–60.
8. van Zuijlen P, etal. Tissue engineering in burn scar reconstruction. Burns Trauma. 2015;3:18.
9. Tang B, Zhu B, Liang Y-Y, Bi L-K, Chen B, Hu Z-C, Zhu J-Y.Early escharectomy and concurrent compos­ite skin grafting over human acellular dermal matrix scaffold for covering deep facial burns. Plast Reconstr Surg. 2011;127(4):1533–8.
10. Stephen L, David H, Maureen H, Yvelle A, Abhijit N. Transplanted acellular allograft dermal matrix: potential as a template for the reconstruction of viable dermis. Transplantation. 1995;60(1):1–9.
11. The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. “Dressings for supercial and partial thickness burns (Review)” 2013.
12. Whitaker IS, Worthington S, Jivan S, Phipps A.The use of biobrane by burn units in the United Kingdom: a national study. Burns. 2007;33:1015–20.
13. Vana LPM, Battlehner CN, Ferreira MA, Caldini EG, Gemperli R, Alonso N.Comparative long-term study between two dermal regeneration templates for the reconstruction of burn scar contractures in humans: clinical and histological results. Burns. 2020;46(3):596–608.
14. Whitaker IS, Prowse S, Potokar TS.A critical evalu­ation of the use of Biobrane as a biologic skin substi­tute: a versatile tool for the plastic and reconstructive surgeon. Ann Plast Surg. 2008;60:333–7.
15. Busche MN, et al. Der Biobrane®-Handschuh bei Verbrennungen der Hand. Handchir Mikrochir Plast Chir. 2009;41:348–54.
16. Gravante G, Delogu D, Giordan N, Morano G, Montone A, Esposito G.The use of Hyalomatrix PA in the treatment of deep partial-thickness burns. J Burn Care Res. 2007;28(2):269–74.
17. Auxenfans C, Shipkov H, Bach C, Catherine Z, Lacroix P, Bertin-Maghit M, Braye F.Cultured allo­genic keratinocytes for extensive burns: a retrospec­tive study over 15 years. Burns. 2014;40(1):82–8.
18. Kesting MR, Wolf K-D, Hohlweg-Majert B, Steinstraesser L. The role of allogenic amniotic membrane in burn treatment. J Burn Care Res. 2008;29(6):907–16.
19. Ang ES, Lee ST, Gan CS, See P, Chan YH, Ng LH, Machin D.The role of alternative therapy in the man­agement of partial thickness burns of the face--expe­rience with the use of moist exposed burn ointment (MEBO) compared with silver sulphadiazine. Ann Acad Med Singap. 2000;29(1):7–10.
20. Berry MG, Goodwin TI, Misra RR, Dunn KW.Digitisation of the total burn surface area. Burns. 2006;32:684–8.
21. Zhang W, et al. Catechol-functionalized hydrogels: biomimetic design, adhesion mechanism, and biomed­ical applications. Chem Soc Rev. 2020;49:433–64.
22. Kopecki Z. Development of next-generation anti­microbial hydrogel dressing to combat burn wound infection. Biosci Rep. 2021;41:2.
23. Alven S, Aderibigbe BA. Chitosan and cellulose­based hydrogels for wound management. Int J Mol Sci. 2020;21(24):9656.
24. Richetta AG, Cantisani C, Li WV, Mattozz C, Melis L, De Gado F, et al. Hydrober dressing and wound repair: review of the literature and new pat­ents. Recent Patents Inamm Allergy Drug Discov. 2011;5(2):150–4.
25. Dinah F, Adhikari A.Gauze packing of open surgical wounds: empirical or evidence-based practice? Ann R Coll Surg Engl. 2006;88:33–6.
26. Jones V, Grey JE, Harding KG. Wound dressings. BMJ. 2006;332:777–80.
27. Giudice G, Filoni A, Maggio G, Bonamonte D, Vestita M, etal. Cost analysis of a novel enzymatic debriding agent for management of burn wounds. Biomed Res Int. 2017;2017:9567498.
28. Kern MA, Depka N, Schackert C, Henkel W, Hirche CR. Enzymatic burn wound debridement with NexoBrid1: cost simulations and investiga­tions on cost efciency. Gesundheitsökonomie und Qualitätsmanagement. 2018;23:21–8.
29. Russo R, Carrizzo A, Barbato A, Rasile BR, Pentangelo P, Ceccaroni A, Marra C, Alfano C, Losco L. Clinical evaluation of the efcacy and tolerabil­ity of Rigenase® and polyhexanide (Fitostimoline® Plus) vs. hyaluronic acid and silver sulfadiazine (Connettivina® Bio Plus) for the treatment of acute skin wounds: a randomized trial. J Clin Med. 2022;11(9):2518.
30. Hoogewerf CJ, Hop MJ, Nieuwenhuis MK, Oen IM, Middelkoop E, Van Baar ME. Topical treat­ment for facial burns. Cochrane Database Syst Rev. 2020;7(7):CD008058.
31. Hirsch T, Ashkar W, Schumacher O, Steinstraesser L, Ingianni G, Cedidi CC.Moist exposed burn ointment (MEBO) in partial thickness burns—a randomized, comparative open mono-center study on the ef­cacy of dermaheal (MEBO) ointment on thermal 2nd degree burns compared to conventional therapy. Eur J Med Res. 2008;13(11):505–10. PMID: 19073386.
32. Isak V, Beerli T, Cozzio A, Flatz L. A rare case of localized argyria on the face. Case Rep Dermatol. 2019;11(1):23–7.
33. Fernandez R, Green HL, Grifths R, Atkinson RA, Ellwood LJ. Water for wound cleansing. Cochrane Database Syst Rev. 2022;9(9):CD003861.
34. Cooper DD, Seupaul RA.Is water effective for wound cleansing? Ann Emerg Med. 2012;60:626–7.
10 Dressing inBurns
https://t.me/medicina_free
111
35. Ryssel H, Kloeters O, Germann G, Schäfer T, Wiedemann G, Oehlbauer M.The antimicrobial effect of acetic acid- an alternative to common local anti­septics? Burns. 2009;35:695–700.
36. Miller LM, Loder JS, Hansbrough JF, Peterson HD, Monafo WW, Jordan MH.Patient tolerance of topical chlorhexidine diphosphanilate: a new topical agent for burns. Burns. 1990;16:217–20.
37. Moriarty R. Corrosive chemicals: acids and alkali. Drug Ther. 1979;1:3.
38. Leonard LG, Scheulen JJ, Munster AM. Chemical burns: effect of prompt rst aid. J Trauma. 1982;22(5):420–3.
39. Yano K, Hata Y, Matsuka K, etal. Effects of washing with a neutralizing agent on alkaline skin injuries in an experimental model. Burns. 1994;20(1):36–9.
40. Palao R, Monge I, Ruiz M, et al. Chemical burns: pathophysiology and treatment. Burns. 2010;36(3):295–304.
41. Kuckelkorn R, Schrage N, Keller G, etal. Emergency treatment of chemical and thermal eye burns. Acta Ophthalmol Scand. 2002;80(1):4–10.
Innovative Dressings
https://t.me/medicina_free
EvelinMakuc
11
As the modern world’s population has become an increasingly aging one, chronic conditions including skin healing disorders have become more and more common, bringing about a huge economic and sanitary burden. Statistics report that, among chronic limb wounds, for example, diabetic foot ulcers are the most common, being responsible for up to 70% of lower limb amputa­tions, and, as a consequence, for increased mor­tality [1].
This and other signicant reasons, which include psychological and social implications of having to deal with poorly healing lesions, have led to the need to develop smart materials that can optimize the management of said conditions.
Progression in knowledge of wound etiology and healing processes has led to the introduction of more technological, advanced dressing materi­als that target specic aspects of the wound, thus optimizing the healing process.
While traditional dressings are still widely used both for their low cost and simple manufac­turing process, these are, however, considered inert dressings, because of the lack of interaction with the wound bed, and inability to create the optimal conditions for an accelerated healing process, unlike advanced dressings [2].
E. Makuc (*) RN and Wound Care Expert at Cattinara Hospital, ASUGI, Trieste, Italy e-mail: evelin.makuc@asugi.sanita.fvg.it
Nowadays, dressings are considered optimal and efcient when they are both cost-effective and deliver specic benecial effects. These include antibacterial properties, pain relief, epi­thelialization acceleration, mechanical protection and exibility, exudate absorption, and dissolv­ing of necrotic tissue and brin [3].
Innovative dressings, besides providing better biocompatibility, moisture retention, and degrad­ability [4], nowadays provide innovative technol­ogy with the use of nanotechnology, micelle matrixes, and antimicrobial agents. They not only function as a protective layer, but also operate as diagnostic sensors in wound monitoring and wound healing promotion.
Wound care dressings can be summarized into three macro-groups: passive, interactive, and bio­active products [5]. While passive dressings are suitable for dry wounds and not for moderately to highly exuding ones, interactive and bioactive ones perform brilliantly: the rst by creating an hypoxic environment that has proven to be highly stimulating re-epithelialization and granulation [6], the second, by delivering bioactive com­pounds to the wound bed.
More in detail, dressings can be further divided into four categories, according to the Italian Association of Chronic Wounds position paper of 2014: [7].
© The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 M. Maruccia et al. (eds.), Pearls and Pitfalls in Skin Ulcer Management,
https://doi.org/10.1007/978-3-031-45453-0_11
113
114
https://t.me/medicina_free
E. Makuc
• Autolysis and debridement promoting dressings.
• Granulation-stimulating dressings.
• Antimicrobial dressings.
• Re-epithelialization promoting dressings.
Some innovative dressing technologies are
listed as follows and will be thoroughly analyzed in this chapter:
• TLC-NOSF Technology-based dressings.
• Gelling hydrober dressings.
• Microbe-trapping dressings.
11.1 TLC-NOSF Technology-Based
Dressings
Technology lipidocolloid with nano-oligo­saccharide factor (TCL-NOSF) is a lipidocolloid matrix containing sucrose octasulfate potassium salt: This salt has proven to actively inhibit matrix metalloproteases (MMPs) and to interact with different growth factors. Lipidocolloid Technology-silver matrix (TLC-Ag)-based dress­ings have been in use since 2006, supported by high-quality medical evidence, for the manage­ment of wounds at high risk or with ongoing infection [8]. This technology can be applied to contact layers, adhesive and non-adhesive foams, and gelifying bers and has lately been used as coating of polyacrylate polyabsorbent bers.
Results from a randomized controlled trial on
chronic leg ulcer treatment [9] and an observa­tional study on 227 patients [10] suggest an increased efcacy of wound healing and reduc­tion in complications following the use of silver­based dressings, as opposed to dressings without silver: TCL-Ag technology has a broad-spectrum antimicrobial effect along with anti-biolm action thanks to the synergic if not enhanced action of the matrix and the polyabsorbent bers that mechanically break down biolm of also methicillin-resistant Staphylococcus aureus (MRSA) and pseudomonas aeruginosa, remain­ing active for up to 7days [11].
Furthermore, it reduces up to 32.5% of the
wound surface after a 4-week treatment and up to
62.5% of slough [12], resulting in an effective, safe dressing in the management of wounds regardless of their level of exudate or healing stage, with superior capacity when compared to commonly used hydrobers [13].
This technology can be applied and combined with different materials, or can be preceded by preparation treatments with dressings containing polyacrylate and hydro-desloughing bers (as in UrgoClean Ag dressing), which are highly absor­bent and trap slough, bacteria, and biolm resi­dues, keeping the wound deterged. Biolm is a structured colony of bacteria enclosed in a poly­saccharide extracellular matrix that takes only 2 to 4days to form and is present in over 80% of infections [14, 15], hindering healing by promot­ing inammation, exudate production, and slough; it also acts as barrier against antimicro­bial molecules, antibodies, and macrophages [16].
Most silver-based dressings have the ion impregnated into the absorbent bers or foam, whereas the silver contained in some advanced dressings like UrgoClean Ag® comes directly in contact with the wound bed because of its incor­poration in the lipidocolloid layer, maximizing its antimicrobial efcacy [11].
Change in these types of dressings may vary according to the clinical conditions and the exu­date level of the wound, approximately every other day.
They are mostly indicated for acute and chronic lesions with and without local infection and are contraindicated in patients with allergies to any of the components.
Another type of polyabsorbent ber dressing containing a protease inhibitor (TLC-NOSF heal­ing matrix that inhibits excess metalloproteinase) and polyabsorbent bers that bind, trap, and retain exudate is UrgoStart Plus®. This is particu­larly indicated for diabetic foot ulcers: Lower limb wounds, diabetic foot, and pressure wounds generally require an average of 210days to heal completely [17, 18].
Along with the underlying causes, three other factors greatly affect the healing: process: excess MMP damages the extracellular matrix and is systematically higher in chronic wounds as
11 Innovative Dressings
https://t.me/medicina_free
115
opposed to acute ones [19]. Vascular alterations limit oxygen supply [20] and slough recurrence perpetuates inammation.
When addressing these issues, physicians must prioritize quality of life, avoidance of fur­ther complications, and reduction of healthcare costs.
That being stated, innovative dressings such as UrgoStart Plus® have proven to reduce that median healing time by 100days on average [21] thanks to its polyabsorbent bers that absorb excess exudate and bind slough and debris through electrostatic mechanism and thanks to its TCL-NOSF matrix technology (Lipidocolloid Technology-Nano-Oligosaccharide Factor). This patented matrix technology, once in contact with the wound bed, hydrates and turns into a gel that creates a favorable healing environment by inhib­iting excess matrix metalloproteinase (MMP) and by promoting angiogenesis through endothe­lial cell migration.
These properties combined make the dressing highly cohesive and provide atraumatic, painless removal [22, 23].
Following adequate treatment of the underly­ing causes (compression, revascularization, etc.), advanced dressing must be changed every other day at the beginning of treatment and subse­quently every 7days considering the level of exu­date and clinical conditions of the wound.
If infection of the wound bed coexists, it is recommended to rst apply a silver-based dress­ing (such as UrgoClean Ag®) before starting a TLC-based treatment.
In light of new scientic evidence proving that TLC-NOSF technology reduces healing time of diabetic foot ulcers by approximately 60 days and heals 60% more patients affected by DFU compared to wounds treated with non-interactive dressings [24], 2019 International Working Group on the Diabetic Foot (IWGDF) guidelines and NICE [25] strongly recommend the use of TLC-NOSF based dressings like UrgoStart for local treatment of neuro-ischemic diabetic foot wounds [26]. It is mainly indicated on lower limb lesions, diabetic foot lesions, and pressure wounds, while contraindications include heavy
bleeding wounds, cancerous wounds, and abscesses.
Polyester bers like those used for UrgoStart Contact® dressing are also efciently combined with lipidocolloidal matrix rich in saccharide fac­tors (TLC-NOSF Technology), which creates a humid environment that stimulates tissue regen­eration, inhibits metalloprotease, excess and pro­motes neoangiogenesis [27].
This polyester weave allows exudate to be transferred to the secondary dressing, preventing internal growth of granulation tissue, while the composition of the bers does not leave dressing fragments that could have pro-inammatory properties.
Because of its exibility and atraumatic pain­less removal, UrgoStart is indicated in the treat­ment of cavitated, hardly accessible, or deep wounds. Ideal dressing change may vary from 2 to 7days according to healing stage and level of exudate, for a total recommended treatment time of at least 8weeks.
Contraindications to the use of this type of dressing include tumor lesions, stulas, and abscess.
11.2 Hydroactive Dressings,
Gelling Fiber Dressings, and3D FIT Technology Dressings
Hydroactive dressings are multilayered, highly absorbent polymer dressings. Some even have a waterproof outer layer, and although hydroactive dressings are similar to foams, they have a differ­ent action for absorbing exudate because they draw uid into the structure of the polymer and trap the exudate to maintain a moist environment, whereas foams absorb exudate by a siphon effect.
The main advantages of the hydroactive dress­ing are that they (1) absorb exudate quickly and effectively, reducing the risk of maceration, and they provide moisture to dry wounds, facilitating faster healing; they do not stick to the wound bed, making removal atraumatic for the patient; they also soothe painful wounds, providing greater
116
https://t.me/medicina_free
E. Makuc
patient comfort and tolerability, and nally protect the wound from bacteria, reducing the risk of infection. Hydroactive dressings are indi­cated for highly exuding wound surface and cav­ity wounds, including pressure injuries, venous leg ulcers, and minor burns. Due to the ability to contract and expand without causing constric­tion, they are particularly useful over joints.
Because of their absorbing abilities, these dressings are not indicated for lightly exuding and dry wounds [28].
Gelling ber dressings are absorbent wound dressings that contain synthetic bers made from sodium carboxymethyl cellulose, strengthening cellulose bers, and other absorbent materials. As wound uid is absorbed into the dressing, a gel forms, which assists in maintaining a moist environment for optimal wound healing and the formation of granulation tissue.
Biatain Fiber® with HexaLock technology is an example of a new gelling ber in the form of rope or sheet dressing with characteristic heat­sealed hexagonal unities that block exudate and maintain their original shape thanks to the inno­vative HexaLock technology [29].
This new dressing can be applied to exuding wounds, especially undermined and cavitary wounds, with the advantage of creating a stron­ger, quicker gelling substance when in contact with the wound bed, as well as better managing the exudate level through absorption, retention, and resistance to shrinkage, when compared with traditional alginate dressings [30].
Like other gelling bers, Biatain Fiber® can also be combined with other super-absorbent dressings, which, however, must conform to the wound edges: Contact with exuding wound bed creates a cohesive gel through vertical absorp­tion, which prevents the surrounding skin from macerating.
In addition to its absorbing properties, Biatain ber greatly supports autolytic debridement and de-sloughing, promoting faster wound healing [29].
3D FIT technology dressings include dress­ings with the ability to perfectly adapt and con­form to the wound bed: These can consist of multilayer, polyurethane adhesive, and non-
adhesive absorbent foams (e.g., Biatain Ag®) with continuously released silver ions that pro­vide antimicrobial properties up to 7 days. The non-adhesive area is in direct contact with the wound bed, while the external hydrophobic sheath protects from external agents.
Thanks to its patented 3D FIT technology, the dressing absorbs all excess exudate, when in con­tact with the wound bed, and molds itself to the wound bed’s shape for up to 2cm of depth.
The adhesive border is delicate on the sur­rounding skin and allows atraumatic removal, leaving no residues. Indicated on acute and chronic wounds with high bacterial presence, with medium to high exudation level. The dress­ing can also have prophylactic use, and dressing change can occur in 5 to 7days. Contraindications: Silver Hypersensitivity [31].
11.3 Dressings withHydrober
andMore Than Silver Technology
“Hydrober” and “more than silver” technology dressings are antimicrobial absorbent dressings developed to counteract biolm on the wound bed.
To accelerate healing, biolm and excess exu­date must be managed.
By placing the dressing on the wound bed, hydrober technology begins to absorb the exu­date and form a cohesive gel ensuring full contact with the wound bed.
“Hydrober” technology is composed of car­boxyl methyl cellulose bers and physically removes and pulls debris and bacteria away from the wound by trapping them inside the dressing.
The “more than silver” technology consists of three components: BEC, EDTA, and Ag+that act synergistically to disrupt and destroy biolm.
Benzethonium chloride (BEC) is a surfactant that reduces surface tension within the biolm and its action helps antibiolm agents reach bac­teria more effectively and faster.
Ethylenediaminetetraacetic acid or disodium salt (EDTA) is a metal chelating agent that selec­tively binds and removes metal ions that hold the
11 Innovative Dressings
https://t.me/medicina_free
117
EPS matrix of the biolm together, exposing the microorganisms within it.
Ag+ Once defenses are down, the ionic sil­ver can reach and kill exposed microorganisms. The concentration of silver is 1.2%, and the dressing provides safe, broad-spectrum antimi­crobial action. Silver ions become available only when the dressing gels, and this modulated action ensures a constant silver level to destroy and pre­vent biolm reproduction.
Strengthening the bers of the dressing allows for increased tensile strength and safe removal in a compact manner without leaving residue [3240].
11.3.1 PluroGel® Burn andWound
Dressing
This is a 100% water-soluble, biocompatible sur­factant gel utilizing micelle matrix technology. This dressing as well comes with or without sil­ver ions and shows autolytic and pro-healing properties.
Slough, bacteria, and debris are effectively trapped and softened by the concentrated surfac­tant that also helps maintain an optimal moist environment.
Its painless removal increases patient compli­ance, while the unique micelle matrix allows the dressing to maintain thickness [41].
PluroGel® Burn and Wound Dressing are indi­cated for use on chronic vascular ulcers, venous ulcers, diabetic ulcers, draining wounds, partial­and full-thickness wounds, pressure injuries, second-degree burns, surgical wounds, trauma wounds (abrasions, lacerations, skin tears), and tunneling/undermining wounds.
It can be applied directly onto secondary dressing using a sterile applicator (foam for a shallow wound, packing strips for a deeper wound). Thickness of 3mm (slightly more than nickel) is ideal for minimal drainage and 5mm (2 nickels thick) for moderate drainage or dressing change every 3days.
Where applicable, the gel can be covered with absorbent dressing and kept for up to 3 days: PluroGel® is 100% water-soluble and can be eas-
ily irrigated from the wound at dressing change using normal dressing change solutions.
Contraindications include use on third- and
fourth-degree burns.
11.3.2 PluroGel® Burn andWound Dressing withPSSD
It consists of a comfortable gel containing PluroGel surfactant concentrate with the addition of antimicrobial silver sulfadiazine: can manage the same lesions listed for PluroGel Burn; how­ever, should not be used in case of known sensi­tivity to sulfadiazine, silver, or sulfonamides.
11.3.3 Issue-Targeting Dressings
Innovative dressings have been developed for the treatment and management of specic skin issues. One of these issues is Intertrigo.
Intertrigo is a form of moisture-associated skin damage and is commonly found in skin-fold areas such as armpits, under the breasts, abdo­men, toes, and groin. It occurs as a result of pro­longed exposure to perspiration and skin-to-skin contact.
Obese individuals are at higher risk of devel­oping intertrigo, and it is exacerbated by factors such as immobility and poor hygiene. Patients may experience itching, and burning sensation, often combined with unpleasant odor, with great affection of quality of life and risk of secondary infection [42].
InterDry® is a product for the management of skin-fold complicated conditions, such as Intertrigo, which targets all three factors associ­ated with skin-fold damage simultaneously: skin moisture, friction, and microbial proliferation, thanks to its antimicrobial silver complex.
The fabric can be shaped and applied in a sin­gle layer after assessing and drying the affected area, making sure to leave at least 5cm of excess fabric to be exposed outside the skin fold to pro­mote evaporation. Each application must not exceed 5 days, after which the fabric must be replaced with a new one.
118
https://t.me/medicina_free
E. Makuc
InterDry has been demonstrated to provide relief and reduction in symptoms such as ery­thema, denudement, maceration, itching, and pain within 5days from application [43, 44].
11.3.4 Activated Carbon-Based
Dressings
Zorex® wound contact dressings accelerate the wound healing process 1 [4547] across a diverse range of wound types. Activated carbon cloth (ACC) has been used for many years as an anti­odor component in wound dressings. The key innovation behind Zorex® activated carbon cloth is the recent discovery that, when in direct contact with the wound bed, helps signicantly accelerate wound healing – attracting and trap­ping the microbes from the wound bed into the activated carbon cloth through electrostatic force. It has proven effective against MRSA and as a protease modulator [47], providing an effective antimicrobial barrier for up to 7days.
Besides reducing pain and exudate, it reduces and controls odor through its highly absorbent properties.
This dressing is indicated for full- and partial­thickness wounds such as traumatic wounds, sur­gical sites, fumigating carcinomas, pressure ulcers, venous leg ulcers, diabetic foot ulcers, and recipient graft sites.
11.4 Copper Antimicrobial
Dressings
Dressings impregnated with copper oxide mic­roparticles are indicated for acute, post-surgical, and chronic wounds such as
• Diabetic wounds.
• Lower extremity ulcers.
• Pressure injuries.
• Supercial epidermal and dermal burns.
• Surgical wounds.
Copper is an essential nutrient mineral with potent broad-spectrum antimicrobial efcacy; it
is safe, biocompatible, nonsensitizing, and non­irritating to the skin.
The dressings are disposable with an inner absorbent layer and one or two outer nonwoven, nonadherent layers. All layers are impregnated with copper oxide particles and can be left in place for up to 7days.
11.4.1 Dialkylcarbamoyl Chloride
(DACC) Technology
Dialkylcarbamoyl chloride (DACC) is a synthetic fatty acid that is highly hydrophobic: Since most microorganisms responsible for chronic wounds have hydrophobic surfaces, invitro data suggest that bacteria and endotoxins naturally bind irre­versibly to the unique DACC-coated dressing and, therefore, unlike other dressings that kill bacteria and the microbes, when these dressings are removed, a great quantity of bacteria and microbes is also removed [48].
This technology can be applied to different materials, coating diverse types of dressings according to the kind of wound and main issue to address.
Cutimed Siltec Sorbact®, for example, con­sists of a super-absorbent foam with a silicone part that comes in contact with the wound bed, while the top part is made of a highly breathable lm. This dressing is designed to greatly manage exudate but also traps bacteria and maintains wound moisture. It can be used for all shallow, contaminated, and colonized or infected wounds with moderate to high exudate level (traumatic wounds, chronic leg ulcers, diabetic and pressure wounds, and fungal infections).
Bacteria-binding properties may be altered if used in combination with creams and ointments, so these are generally not recommended when using Cutimed Siltec Sorbact. Cutimed Sorbact dressing pad, instead, is an exudate absorbing and bacteria-binding dressing that is coated with DACC technology. It best works in a moist envi­ronment and can be used for all traumatic and nontraumatic chronic wounds with low levels of exudate. As with Cutimed Siltec Sorbact, oint­ments and creams are not recommended in
11 Innovative Dressings
https://t.me/medicina_free
119
combination with this dressing to not alter its bacteria-binding properties.
Gels and hydrogels, like Cutimed Sorbact Gel®, can be also used for the management of low levels of exudate and to bind bacteria in sloughy wounds. Combination with hydropolymer gel sheets for Cutimed Sorbact Hydroactive® is designed to reduce wound bioburden, as well as absorb and lock in exudate while maintaining a moist environment. Moreover, its non-adhesive borders make its removal atraumatic for the patient.
11.5 Primary Wound Dressing
Spray
Medicament based on natural extracts derived from two plants, Hypericum perforatum or St. John’s Wort and Azadirachta indica, A. Juss or Neem tree that are found to have anti­inammatory, healing, antibacterial properties against Gram-negative and Gram-positive micro­organisms as well as biocidal and repellent effects against harmful dipterans.
The commercial product 1—Primary wound dressing (1PWD®) derived from the ENEA pat­ent is a plant-based, non-single-molecule, truly effective (evidence-based) preparation with “all­in- one” characteristics as primary dressing, applicable at any stage of the wound, i.e., from the moment of injury and until complete healing, which allows the resolution of all wounds both acute and chronic, unlike the countless treatment protocols, which involve the simultaneous or suc­cessive use of different products.
The medicament exerts a powerful attractive ability to macrophages responsible for infection control in the wound bed, which disappear during the granulation phase. The initial phase of the scarring process is dominated by the inamma­tory phase, which is characterized by local acti­vation of the innate immune system, resulting in an immediate inux of polymorphonuclear leu­kocytes (neutrophils) followed by subsequent invasion of blood monocytes that differentiate into tissue macrophages, which are essential for
the regulation of immune responses and proper course of inammation.
The medicament promotes re-epithelializa­tion by controlling the proliferation of keratino­cytes along the wound margins already in the inammatory phase, which will then serve to re- epithelialize the granulation tissue in preparation.
References
1. Lindholm C, Searle R. Wound management for the 21st century: combining effectiveness and efciency. Int Wound J. 2016;13:5.
2. Broughton G II, Janis J, Attinger CE.A brief history of wound care. Plast Reconstr Surg. 2006;117:6S–11S.
https://doi.org/10.1097/01.prs.0000225429.76355.dd.
3. Mirhaj M, Labbaf S, Tavakoli M, Seifalian AM.Emerging treatment strategies in wound care. Int Wound J. 2022;19(7):1934.
4. Hopper GP, Deakin AH, Crane EO, Clarke J. Enhancing patient recovery following lower limb arthroplasty with a modern wound dressing: a prospec­tive, comparative audit. J Wound Care. 2012;21:200–
3. https://doi.org/10.12968/jowc.2012.21.4.200.
5. Ochoa M, Rahimi R, Zhou J, Jiang H, Yoon CK, Maddipatla D, Narakathu BB, Jain V, Oscai MM, Morken TJ, Oliveira RH, Campana GL, Cummings OW, Zieger MA, Sood R, Atashbar MZ, Ziaie B. Integrated sensing and delivery of oxygen for next-generation smart wound dressings. Microsyst Nanoeng. 2020;6:46.
6. Hong WX, Hu MS, Esquivel M, Liang GY, Rennert RC, McArdle A, Paik KJ, Duscher D, Gurtner GC, Lorenz HP. The role of hypoxia-inducible factor in wound healing. Adv Wound Care (New Rochelle). 2014;3:390.
7. Greco A, Mastronicola D, Magnoni C. Functional classication of wound dressings. AIUC posi­tion document on wound dressing. Acta Vulnol. 2014;12(3):143–52.
8. Dissemond J, Lützkendorf S. Clinical evalua­tion of polyabsorbent TLC-NOSF dressings on chronic wounds: a prospective, observational, mul­ticentre study of 1140 patients. J Wound Care. 2020;29(6):350–61.
9. Lazareth I, Meaume S, Sigal-Grinberg ML, et al. Efcacy of a silver lipidocolloid dressing on heav­ily colonised wounds: a republished RCT. J Wound Care. 2012;21(2):96–102. https://doi.org/10.12968/
jowc.2012.21.2.96.
10. Dissemond J, Dietlein M.Use of a TLC-Ag dressing on 2270 patients with wounds at risk or with signs of local infection: an observational study. J Wound Care. 2020;29(3):162.
Соседние файлы в папке @xirurgi_2025